Valuation check: 8279.TWO's profit margin is 10.0%, below the Healthcare sector average of 17.63%.
Get informed when a big investor buys or sells
+ FollowAs of Sep 2026
Trailing 12 months ending Sep 2026
Syngen Biotech ,Ltd. posts a profit margin of 10.0% as of September 2026. That compares with 13.71% in the prior-year period — down 27.1% year over year. That is below the Healthcare sector average of 17.63%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
In the prior comparable period, Syngen Biotech ,Ltd.'s profit margin was 13.71%. The latest reading is 10.0% — a 27.1% year-over-year decrease (period ending September 2026). Use the history and growth charts on this page for a longer lookback.
For Healthcare stocks, a profit margin near 17.63% is typical. Syngen Biotech ,Ltd.'s 10.0% is lower that level. That is roughly 43.3% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.
Syngen Biotech ,Ltd.'s profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 10.0% as of September 2026; use YoY and peer views to separate noise from signal.
Context for 8279.TWO's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 17.63%), and (3) consistency with growth and profitability. This page covers the first two; Syngen Biotech ,Ltd.'s other metric pages and overview cover the third.